We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Promising Therapy for Alzheimer's

By Biotechdaily staff writers
Posted on 26 Apr 2005
In what may prove to be a landmark development, a new clinical study has provided encouraging evidence that antibodies derived from human plasma can capture the beta-amyloid protein in blood and exert positive effects on the thinking abilities of patients with Alzheimer's disease (AD).

Intravenous immunoglobulin (IVIg) has been found to contain antibodies that latch onto beta-amyloid proteins in the blood. More...
Prior studies have shown that these antibodies can draw beta-amyloid out of the nervous system and reduce the burden of amyloid on the brain. However, AD patients were found to have lower levels of anti-amyloid antibodies in their blood than cognitively normal individuals their age. Later on, researchers discovered that IVIg contained antibodies to several forms of beta-amyloid, including those thought to play a central role in the development of AD.

In the phase I trial, eight AD patients were treated with IVIg and, to date, seven have undergone cognitive testing after six months of therapy. The testing showed that cognitive function not only stopped declining in all seven patients but also improved in six of the seven.

"If these results are confirmed in larger, controlled trials, we might have a safe Alzheimer's treatment capable of clearing the amyloid protein away,” observed senior researcher Dr. Marc E. Weksler, professor of geriatric medicine at Weill Cornell Medical College (New York, NY, USA).

The AD patients on the study had mild-to-moderate AD and averaged 74 years of age. They received one to four IVIg infusions per month at varying doses. Since the researchers wanted to track circulating levels of beta-amyloid and beta-amyloid antibodies, patients also underwent regular blood tests, as well as spinal taps to collect samples of spinal fluid. Patients were also given standard tests of memory and cognition to assess ongoing changes in their mental function. The study findings were presented at the annual meeting of the American Academy of Neurology in Miami (FL, USA) in April 2005.

In spite of the encouraging results, the scientists and doctors involved remained cautious. "Right now, we'd advise doctors against treating Alzheimer's patients with IVIg,” they stated. "There's still too much we don't know--especially the treatment's long-term effectiveness. We need to confirm these findings in larger, controlled trials before we can say anything definite.”





Related Links:
Weill Cornell Medical Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.